Loading...
Market
Will Roche integrate Poseida's technologies into its cancer pipeline by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Roche's official press releases or financial reports
Story
Roche Completes $1.5 Billion Acquisition of Poseida Therapeutics, Securing 66% Stake by January 8
Jan 8, 2025, 12:15 PM
Roche Holdings AG has successfully completed its tender offer for Poseida Therapeutics, Inc., acquiring a 66% stake in the U.S. genetic engineering firm. The transaction, valued at approximately $1.5 billion, aims to enhance Roche's capabilities in developing new cancer treatments. The acquisition is set to finalize on January 8, 2025, following the completion of the tender offer, which saw significant participation from shareholders.
View original story
Similar markets
Yes • 50%
No • 50%
Pfizer • 25%
Other • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
10,000 to 50,000 • 25%
Less than 10,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
